Jessica Ann Walsh
( out of 43 reviews )

Jessica Ann Walsh, MD

Languages spoken: English

Clinical Locations

University of Utah Hospital

Rheumatology, Area E
Salt Lake City
801-581-7724

  • Jessica Walsh, MD, is an Associate Professor at the University of Utah School of Medicine and George E. Wahlen Veteran Affairs Medical Center. As a Rheumatologist, her clinical interests include psoriatic diseases and spondyloarthritis. She developed and serves as the Director of the Spondyloarthritis Clinic. She is the Co-Director of the Combined Psoriatic Diseases Clinic in which psoriatic patients are jointly cared for by a rheumatologist and a dermatologist during the same clinic visit.




    Walsh received her Medical Degree and Rheumatology training from the University of Utah. She is board certified in Internal Medicine and Rheumatology. She is currently a member and keynote speaker for the Spondyloarthritis Association of America and the National Psoriasis Foundation.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Rheumatology)

    Patient Rating

    4.9 /5
    ( out of 43 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 18, 2024
    UH HOSPITALS AND CLINICS

    Thank you Dr Walsh for being caring and kind. And for spending extra time with our patient, your recommendations and great info you provided us!

    October 11, 2024
    UH HOSPITALS AND CLINICS

    Dr Walsh is amazing. She is very , lets me participate in my care, she is amazing.

    September 28, 2024
    UH HOSPITALS AND CLINICS

    I would recommend that you give Dr. Walsh a chance to help you feel better and do better. I think you would be amazed to know how wonderful it is to go to a referral center and help people that specialize only in one area, and treat that area that you're affected with, with the latest and best care that's available. You're worth it.

    September 15, 2024
    UH HOSPITALS AND CLINICS

    She is the best Dr I've ever seen to treat my Psoriatic arthritis. She's thorough, addresses every issue I have, everytime, and tries to help find a doable solution. I absolutley Love Dr Walsh. She is so good that she's next to impossible to get an appointment with.

    June 07, 2024
    UH HOSPITALS AND CLINICS

    As I said, Dr. Walsh treats the whole patient. She remembers things about me and my life, and she watches for ways or treatments that may improve my life. I think she is an excellent doctor!

    June 02, 2024
    UH HOSPITALS AND CLINICS

    Dr Walsh is a very caring Dr. I feel that she really listens to my challenges and works to find the best resolutions, including me in all options, and we decide together which things to utilize in finding the best things to help me.

    May 10, 2024
    UH HOSPITALS AND CLINICS

    Dr. Jessica Walsh is absolutely a Class Act. She spent so much personal time with me. She educates me each time we see each other. I trust her with my life and she's pulled me through some tough times. She truly is wonderful and very thorough.

    May 03, 2024
    UH HOSPITALS AND CLINICS

    The The assistant was very nice and she she explained everything to me so I can understand.

    March 08, 2024
    UH HOSPITALS AND CLINICS

    Very professional and pleasant. Thanks for your kind attention.

    See More Patient Comments

  • Jessica Walsh, MD, is an Associate Professor at the University of Utah School of Medicine and George E. Wahlen Veteran Affairs Medical Center. As a Rheumatologist, her clinical interests include psoriatic diseases and spondyloarthritis. She developed and serves as the Director of the Spondyloarthritis Clinic. She is the Co-Director of the Combined Psoriatic Diseases Clinic in which psoriatic patients are jointly cared for by a rheumatologist and a dermatologist during the same clinic visit.




    Walsh received her Medical Degree and Rheumatology training from the University of Utah. She is board certified in Internal Medicine and Rheumatology. She is currently a member and keynote speaker for the Spondyloarthritis Association of America and the National Psoriasis Foundation.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Dermatology -Adjunct
    Academic Divisions Rheumatology
    Board Certification
    American Board of Internal Medicine (Sub: Rheumatology)

    Education history

    Graduate Training Clinical Investigation - University of Utah M.S.C.I
    Rheumatology - University of Utah School of Medicine Fellow
    Chief Resident Internal Medicine - University of Utah School of Medicine Chief Resident
    Internal Medicine - University of Utah School of Medicine Resident
    Internship Internal Medicine - University of Utah School of Medicine Intern
    Medicine - University of Utah M.D.
    Graduate Training Business Administration - Boise State University M.B.A.
    Biology - Whitman College B.A.

    Selected Publications

    Journal Article

    1. Deodhar A, Kivitz AJ, Magrey M, Walsh JA, Mease PJ, Greenwald M, Kianifard F, Elam C, Bommidi GM, Winseck A, Gensler LS (2024). A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment. Rheumatology (Oxford). (Read full article)
    2. Nowell WB, Gavigan K, Garza K, OBeirne R, Safford M, George M, Ogdie A, Walsh JA, Danila MI, Venkatachalam S, Stradford L, Rivera E, Curtis JR (2024). Which Educational Topics and Smartphone App Functions Are Prioritized by US Patients With Rheumatic and Musculoskeletal Diseases? A Mixed-Methods Study. J Rheumatol. (Read full article)
    3. Baraliakos X, Saffore CD, Collins EB, Parikh B, Ye X, Walsh JA (2024). Comparative Efficacy of Advanced Therapies in the Treatment of Radiographic Axial Spondyloarthritis or Ankylosing Spondylitis as Evaluated by the ASDAS Low Disease Activity Criteria. Rheumatol Ther. (Read full article)
    4. Walsh JA, Pei S, Alexander S, Braaten T, Walker JH, Clewell J, Douglas KM, Penmetsa GK, Ye X, Breviu B, Cannon GW, Kunkel GA, Sauer BC (2024). Missed opportunities for treatment of inflammatory arthritis and factors associated with non-treatment: An observational cohort study in United States Veterans with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Semin Arthritis Rheum, 66, 152436. (Read full article)
    5. Carroll C, Aalsteinsson J, Prouty M, Duffin KC, Krueger GG, Walsh JA, Feng BJ (2024). Measuring Psoriasis Severity at Home. J Vis Exp, (205). (Read full article)
    6. Walsh JA, Saffore CD, Collins EB, Ostor A (2023). Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis. Rheumatol Ther, 10(5), 1385-1398. (Read full article)
    7. Walsh JA, Carroll C, Callis Duffin K, Wang J, Krueger GG, Feng BJ (2023). PAPRIKA: A Question Bank for Assessing Psoriatic Arthritis Risk in Individuals of Diverse Ancestries. Arthritis Care Res (Hoboken), 76(3), 421-425. (Read full article)
    8. Kiltz U, Kishimoto M, Walsh JA, Sampaio-Barros P, Mittal M, Saffore CD, Wung P, Ganz F, Biljan A, Poddubnyy D (2023). Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2. Rheumatol Ther, 10(4), 887-899. (Read full article)
    9. Magrey M, Walsh JA, Flierl S, Howard RA, Calheiros RC, Wei D, Khan MA (2023). The International Map of Axial Spondyloarthritis Survey: A US Patient Perspective on Diagnosis and Burden of Disease. ACR Open Rheumatol, 5(5), 264-276. (Read full article)
    10. Baraliakos X, Ranza R, str A, Ciccia F, Coates LC, Rednic S, Walsh JA, Douglas K, Gao T, Kato K, Song IH, Ganz F, Deodhar A (2023). Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies. Arthritis Res Ther, 25(1), 56. (Read full article)
    11. Karmacharya P, Stull C, Stephens-Shields A, Husni ME, Scher JU, Craig E, Fitzsimmons R, Reddy SM, Magrey MN, Ogdie A, Walsh JA (2023). Responsiveness and minimal clinically important difference in patient-reported outcome measures among patients with psoriatic arthritis. Arthritis Care Res (Hoboken). (Read full article)
    12. Sen R, Kim E, Napier RJ, Cheng E, Fernandez A, Manning ES, Anderson ER, Maier KD, Hashim M, Kerr GS, Fang MA, Hou JK, Chang E, Walsh JA, Raychadhuri SP, Reimold A, Caplan L (2022). Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Biomarkers in Axial Spondyloarthritis: Observational Studies From the Program to Understand the Longterm Outcomes in Spondyloarthritis Registry. Arthritis Rheumatol, 75(2), 232-241. (Read full article)
    13. Walsh JA, Ogdie A, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Dalby CM, Chakravarty SD, Dennis N, Gossec L (2023). Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and Europe. Joint Bone Spine, 105534. (Read full article)
    14. Pizzicato LN, Vadhariya A, Birt J, Ketkar AG, Bolce R, Grabner M, Pepe RS, Walsh JA (2022). Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States. J Manag Care Spec Pharm, 29, 1-12. (Read full article)
    15. Sen R, Kim E, Napier RJ, Cheng E, Fernandez A, Manning ES, Anderson ER, Maier KD, Hashim M, Kerr GS, Fang MA, Hou JK, Chang E, Walsh JA, Raychadhuri SP, Reimold A, Caplan L (2022). Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as biomarkers in axial spondyloarthritis: observational studies from the PULSAR registry. Arthritis Rheumatol, 75(2), 232-241. (Read full article)
    16. Gossec L, Walsh JA, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Chakravarty SD, Ogdie A (2022). Women with Psoriatic Arthritis Experience Higher Disease Burden than Men: Findings from a Real-World Survey in the USA and Europe. J Rheumatol.
    17. Gossec L, Walsh JA, Michaud K, Holdsworth E, Peterson S, Meakin S, Yang F, Booth N, Chakravarty SD, Piercy J, Dennis N, Ogdie A (2022). Impact of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey. J Rheumatol, 49, 1221-1228. (Read full article)
    18. Braun J, Kiltz U, Deodhar A, Tomita T, Dougados M, Bolce R, Sandoval D, Lin CY, Walsh J (2021). Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. RMD Open, 8(2). (Read full article)
    19. van der Horst-Bruinsma IE, de Vlam K, Walsh JA, Bolce R, Hunter T, Sandoval D, Zhu D, Geneus V, Soriano ER, Magrey M (2022). Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials. Adv Ther, 39(6), 2806-2819. (Read full article)
    20. Gavigan K, Nowell WB, Hunter T, Curtis JR, Malatestinic WN, Bolce RJ, Lisse JR, Walsh J (2022). Employment, Work Productivity, and Biologic Treatments in Self-Reported Axial Spondyloarthritis: a Cross-Sectional Study in a Female Predominant Population from the ArthritisPower Registry. Rheumatol Ther, 9(2), 663-677. (Read full article)
    21. Ogdie A, Myers K, Mansfield C, Tillett W, Nash P, Leach C, Nowell WB, Gavigan K, Zueger P, McDearmon-Blondell E, Walsh J (2022). Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry. Rheumatol Ther, 9(2), 735-751. (Read full article)
    22. Walsh JA, Magrey MN, Baraliakos X, Inui K, Weng MY, Lubrano E, van der Heijde D, Boonen A, Gensler LS, Strand V, Braun J, Hunter T, Li X, Zhu B, Len L, Calderon DMS, Kiltz U (2022). Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial. Arthritis Care Res (Hoboken), 74(3), 451-460. (Read full article)
    23. Walsh JA, Callis Duffin K, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Teeple A, Rowland K, Uy J, McLean RR, Malley W, Cronin A, Merola JF (2021). Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry. Dermatol Ther (Heidelb), 12(1), 97-119. (Read full article)
    24. Nowell WB, Gavigan K, Hunter T, Bolce RJ, Lisse JR, Himelein C, Dubey S, Curtis JR, Walsh JA (2021). Patient Perspectives on Biologics for Axial Spondyloarthritis in a Cross-sectional Study in a Predominantly Female Population: Treatment Satisfaction, Wear-off Between Doses, and Use of Supplemental Medication. Rheumatol Ther, 9, 509-520. (Read full article)
    25. Walsh JA, Magrey M (2020). Clinical Manifestations and Diagnosis of Axial Spondyloarthritis. J Clin Rheumatol, 27(8), e547-e560. (Read full article)
    26. Orbai AM, Reddy SM, Dennis N, Villacorta R, Peterson S, Mesana L, Chakravarty SD, Lin I, Karyekar CS, Wang Y, Pacou M, Walsh J (2021). Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020. Clin Rheumatol, 40(12), 4933-4942. (Read full article)
    27. Nowell WB, Gavigan K, Hunter T, Malatestinic WN, Bolce RJ, Lisse JR, Himelein C, Curtis JR, Walsh JA (2021). Treatment Satisfaction and Decision-making from the Patient Perspective in Axial Spondyloarthritis: Real-World Data from a Descriptive Cross-sectional Survey Study from the ArthritisPower Registry. ACR Open Rheumatol, 4, 85-94. (Read full article)
    28. Bekele DI, Cheng E, Reimold A, Geier C, Ganuthula K, Walsh JA, Clegg DO, Dubreuil M, Kaushik P, Ng B, Chang E, Duong R, Park J, Kerr GS (2021). Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis. Rheumatol Int, 42, 1925-1937. (Read full article)
    29. Belman S, Walsh JA, Carroll C, Milliken M, Haaland B, Duffin KC, Krueger GG, Feng BJ (2021). Psoriasis Characteristics for the Early Detection of Psoriatic Arthritis. J Rheumatol, 48(10), 1559-1565. (Read full article)
    30. Ogdie A, Walsh JA, Chakravarty SD, Peterson S, Lo KH, Kim L, Li N, Hsia EC, Chan EKH, Kavanaugh A, Husni ME (2021). The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. Clin Rheumatol, 40(9), 3667-3677. (Read full article)
    31. Wan MT, Walsh JA, Craig ET, Husni ME, Scher JU, Reddy SM, Leung YY, Ogdie A (2020). A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health. Rheumatology (Oxford), 60(5), 2307-2316. (Read full article)
    32. Walsh JA, Pei S, Penmetsa GK, Overbury RS, Clegg DO, Sauer BC (2020). Identifying Patients With Axial Spondyloarthritis in Large Datasets: Expanding Possibilities for Observational Research. J Rheumatol, 48(5), 685-692. (Read full article)
    33. Walsh JA, Cai Q, Lin I, Pericone CD, Chakravarty SD (2021). Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study. Adv Ther, 38(5), 2353-2364. (Read full article)
    34. Kiltz U, Wei JC, van der Heijde D, van den Bosch F, Walsh JA, Boonen A, Gensler LS, Hunter T, Carlier H, Dong Y, Li X, Bolce R, Strand V, Braun J (2020). Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. J Rheumatol, 48(2), 188-197. (Read full article)
    35. Magrey MN, Danve AS, Ermann J, Walsh JA (2020). Recognizing Axial Spondyloarthritis: A Guide for Primary Care. Mayo Clin Proc, 95(11), 2499-2508. (Read full article)
    36. Walsh JA, Magrey MN, Baraliakos X, Inui K, Weng MY, Lubrano E, van der Heijde D, Boonen A, Gensler LS, Strand V, Braun J, Hunter T, Li X, Zhu B, Len L, Marcelino Sandoval Calderon D, Kiltz U (2020). Ixekizumab Improves Functioning and Health in the Treatment of Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results, COAST-X Trial. Arthritis Care Res (Hoboken), 74, 451-460. (Read full article)
    37. Walsh JA, Wan MT, Willinger C, Husni ME, Scher JU, Reddy SM, Ogdie A (2019). Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease. J Rheumatol, 47(10), 1496-1505. (Read full article)
    38. Walsh JA, Cai Q, Lin I, Fitzgerald T, Pericone CD, Chakravarty SD (2020). Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies. Curr Med Res Opin, 36(7), 1245-1252. (Read full article)
    39. Overbury RS, Pei S, Breviu B, Clegg DO, Walsh JA (2020). Obstructive sleep apnea and fatigue in patients with inflammatory arthritis taking TNF-inhibitors. Int J Clin Rheumtol, 15(3), 38.
    40. Haberman RPerez-Chada LMSiegel EReginato AMWebster DChandran VWalsh JRosen CFReddy SOgdie AScher JUMerola JF (2020). Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2018 Annual Meeting Summary. Rheumatol Int, 5(2), 68-72. (Read full article)
    41. Haberman R, Perez-Chada L, Siegel E, Reginato A, Webster D, Chandran V, Walsh JA Rosen C, Reddy S, Ogdie A, Scher J, Merola J (2020). Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2018 Annual Meeting Summary. J Psoriasis Psoriatic Arthritis.
    42. Dougados M, Wei JC, Landew R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS, COAST-V and COAST-W Study Groups (2019). Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis, 79(2), 176-185. (Read full article)
    43. Walsh JA, Pei S, Penmetsa G, Hansen JL, Cannon GW, Clegg DO, Sauer BC (2019). Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods. J Rheumatol, 47(1), 42-49. (Read full article)
    44. Deodhar A, Gensler LS, Magrey M, Walsh JA, Winseck A, Grant D, Mease PJ (2019). Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap. Rheumatol Ther, 6(4), 487-501. (Read full article)
    45. Walsh JA, Pei S, Penmetsa GK, Sauer BC, Patil V, Walker JH, Clewell J, Douglas KM, Clegg DO, Cannon GW, Halwani A (2019). Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis. J Manag Care Spec Pharm, 25(11), 1218-1228. (Read full article)
    46. Farahi JM, Lynn D, Anand P, Walsh JA, Hashim M, Duong R, Dellavalle RP, Reimold A, Kerr GS, Richards JS, Chang E, Kaushik P, Dubreuil M, Caplan L (2019). A Prospective Cross-Sectional Analysis of Construct Validity for the PALMPASS, A Brief Patient-Reported Outcome Measure for Psoriasis. J Psoriasis Psoriatic Arthritis, 4(4), 186-191. (Read full article)
    47. Walsh J, Hunter T, Schroeder K, Sandoval D, Bolce R (2019). Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006-2016. BMC Rheumatol, 3, 39. (Read full article)
    48. Mease P, Walsh JA, Baraliakos X, Inman R, de Vlam K, Wei JC, Hunter T, Gallo G, Sandoval D, Zhao F, Dong Y, Bolce R, Marzo-Ortega H (2019). Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. Rheumatol Ther, 6(3), 435-450. (Read full article)
    49. Coit P, Kaushik P, Caplan L, Kerr G, Walsh JA, Dubreuil M, Reimold A, Sawalha A (2019). Genome-wide DNA methylation analysis in ankylosing spondylitis identifies HLA-B*27 dependent and independent DNA methylation changes in whole blood. J Autoimmun, 102, 126-132.
    50. Walsh JA, Rozycki M, Yi E, Park Y (2019). Application of machine learning in the diagnosis of axial spondyloarthritis. Curr Opin Rheumatol, 31(4), 362-367. (Read full article)
    51. Braaten TJ, Zhang C, Presson AP, Breviu B, Clegg DO, Walsh JA (2019). Gender Differences in Psoriatic Arthritis with Fatigue, Pain, Function and Work Disability. J Psoriasis Psoriatic Arthritis, 4(4), 192-197.
    52. Walsh JA, Song X, Kim G, Park Y (3/24/2019). Counting the Costs of Ankylosing Spondylitis. 2517(106), 82-85.
    53. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J (2018). Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care Res (Hoboken), 71(1), 2-29. (Read full article)
    54. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J (2018). Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol, 71(1), 5-32. (Read full article)
    55. Walsh JA, Gottlieb AB, Hoepken B, Nurminen T, Mease PJ (2018). Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Clin Rheumatol, 37(12), 3285-3296. (Read full article)
    56. Walsh JA, Song X, Kim G, Park Y (2018). Healthcare Utilization and Direct Costs in Patients with Ankylosing Spondylitis Using a Large US Administrative Claims Database. Rheumatol Ther, 5(2), 463-474. (Read full article)
    57. Walsh JA, Song X, Kim G, Park Y (2018). Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set. J Cardiol Cardiovasc Sci, 2(6), 17-23.
    58. Walsh JA, Jones H, Mallbris L, Duffin KC, Krueger GG, Clegg DO, Szumski A (2018). The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA. Psoriasis (Auckl), 8, 65-74. (Read full article)
    59. Walsh JA, Pei S, Penmetsa GK, Leng J, Cannon GW, Clegg DO, Sauer BC (2018). Cohort identification of axial spondyloarthritis in a large healthcare dataset: current and future methods. BMC Musculoskelet Disord, 19(1), 317. (Read full article)
    60. Walsh JA, Adejoro O, Chastek B, Palmer JB, Hur P (2018). Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses form an Administrative Claims Database  . J Manag Care Spec Pharm, 24(7), 623-31. (Read full article)
    61. Walsh JA, Arledge T, Nurminen T, Peterson L, Stark J (2018). PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol. J Rheumatol, 45(7), 922-928. (Read full article)
    62. Walsh JA, Song X, Kim G, Park Y (2018). Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set. Clin Rheumatol, 37(7), 1869-1878. (Read full article)
    63. Walsh JA, Song X, Kim G, Park Y (2018). Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set. J Pharm Health Serv Res, 9(2), 115-121. (Read full article)
    64. Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, Gmez-Reino JJ, Aelion JA, ACTIVE investigators (2018). Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis, 77(5), 690-698. (Read full article)
    65. Walsh JA, Adejoro O, Chastek B, Park Y (2017). Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. J Comp Eff Res, 7(4), 369-380. (Read full article)
    66. Walsh JA, Pei S, Burningham Z, Penmetsa G, Cannon GW, Clegg DO, Sauer BC (2017). Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance. J Rheumatol, 45(3), 430-436. (Read full article)
    67. Walsh JA, Tan H, Valdez H, Callis Duffin K (2017). Comparative Assessment of PASI and Variations of PGA×BSA as Measures of Psoriasis Severity. J Psoriasis Psoriatic Arthritis, 2(4), 113-118.
    68. van der Heijde D, Dougados M, Landew R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A (2017). Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford), 56(9), 1498-1509. (Read full article)
    69. Walsh JA, Shao Y, Leng J, He T, Teng CC, Redd D, Treitler Zeng Q, Burningham Z, Clegg DO, Sauer BC (2017). Identifying Axial Spondyloarthritis in Electronic Medical Records of US Veterans. Arthritis Care Res (Hoboken), 69(9), 1414-1420. (Read full article)
    70. Sauer BC, Teng CC, He T, Leng J, Lu CC, Walsh JA, Shah N, Harrison DJ, Tang DH, Cannon GW (2016). Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis. J Med Econ, 19(1), 34-43. (Read full article)
    71. Jones BB, Millsop JW, Walsh JA, Krueger GG, Callis Duffin K (2015). Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients. Br J Dermatol, 173(1), 272-4. (Read full article)
    72. Walsh JA, Zhou X, Clegg DO, Teng C, Cannon GW, Sauer B (2015). Mortality in American Veterans with the HLA-B27 gene. J Rheumatol, 42(4), 638-44. (Read full article)
    73. Sieper J, Landew R, Rudwaleit M, van der Heijde D, Dougados M, Mease PJ, Braun J, Deodhar A, Kivitz A, Walsh J, Hoepken B, Nurminen T, Maksymowych WP (2014). Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. Arthritis Rheumatol, 67(3), 668-77. (Read full article)
    74. Kinard K, Walsh JA, Penmetsa GK, Warner JEA (2014). Adalimumab and non-arteritic anterior ischaemic optic neuropathy: A case report. Neuroophthalmology, 38(5), 272-277. (Read full article)
    75. Coates LC, Walsh J, Haroon M, FitzGerald O, Aslam T, Al Balushi F, Burden AD, Burden-Teh E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS (2013). Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools. Arthritis Care Res (Hoboken), 66(9), 1410-6. (Read full article)
    76. Walsh JA, McFadden ML, Morgan MD, Sawitzke AD, Duffin KC, Krueger GG, Clegg DO (2014). Work productivity loss and fatigue in psoriatic arthritis. J Rheumatol, 41(8), 1670-4. (Read full article)
    77. Boehncke WH, Qureshi A, Merola JF, Thai D, Krueger GG, Walsh J, Kim N, Gottlieb AB (2013). Diagnosing and treating psoriatic arthritis: an update. Br J Dermatol, 170(4), 772-86. (Read full article)
    78. Walsh JA, McFadden M, Woodcock J, Clegg DO, Helliwell P, Dommasch E, Gelfand JM, Krueger GG, Duffin KC (2013). Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol, 69(6), 931-7. (Read full article)
    79. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, McHugh N, Mease PJ, Strand V, Waxman R, Azevedo VF, Beltran Ostos A, Carneiro S, Cauli A, Espinoza LR, Flynn JA, Hassan N, Healy P, Kerzberg EM, Lee YJ, Lubrano E, Marchesoni A, Marzo-Ortega H, Porru G, Moreta EG, Nash P, Raffayova H, Ranza R, Raychaudhuri SP, Roussou E, Scarpa R, Song YW, Soriano ER, Tak PP, Ujfalussy I, de Vlam K, Walsh JA (2012). The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis, 72(6), 986-91. (Read full article)
    80. Walsh JA, Callis Duffin K, Krueger GG, Clegg DO (2013). Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. J Rheumatol, 40(3), 287-93. (Read full article)
    81. Zamboni WC, Houghton PJ, Hulstein JL, Kirstein M, Walsh J, Cheshire PJ, Hanna SK, Danks MK, Stewart CF (1999). Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemother Pharmacol, 43(4), 269-76. (Read full article)

    Abstract

    1. Ogdie-Beatty A, Magrey M, Fitzsimmons R, Abdollahi S, Biljan A, Saffore C, Walsh JA (2021). Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists in an Academic Health System: A Retrospective Study [Abstract]. 73(suppl 10).
    2. Penmetsa GK, Pei S, Sauer BC, Douglas K, Walker J, Clewell J, Feng B, Walsh JA (2021). Identifying Erosive Disease from Radiology Reports of Veterans with Inflammatory Arthritis with Natural Language Processing [Abstract]. 73(suppl 10).
    3. Sen R, Kim E, Cheng E, Ganuthula K, Fang M, Kerr G, Walsh JA, Chang E, Raychaudhuri S, Reimold A, Caplan L (2021). A Tough Cell: The Argument for a Biomarker of Clinical and Imaging Outcomes in Spondyloarthritis: The Neutrophil Lymphocyte Ratio and the Platelet Lymphocyte Ratio [Abstract]. 73(suppl 10).
    4. Breviu B, Pei S, Kirkpatrick M, Feng B, Walsh JA (2021). Increased Risk for Inflammatory Arthritis in Veterans with Depression or Anxiety [Abstract]. 73(suppl 10).
    5. Braaten T, Pei s, Rathod A, Penmetsa G, Douglas K, Walker J, Clewell J, Walsh JA (2021). Predictors of Treatment for Inflammatory Arthritis with Immune Modulating Medications (IMM) in US Veterans [Abstract]. 73(suppl 10).